期刊
DRUGS & AGING
卷 38, 期 5, 页码 355-373出版社
ADIS INT LTD
DOI: 10.1007/s40266-021-00853-7
关键词
-
资金
- Medical Research Council [MR/T008199/1] Funding Source: Medline
Current treatments for neurodegenerative diseases in older adults focus on symptom relief, but there is a growing need to identify disease-modifying drugs. Incretin-based therapies for diabetes may also be beneficial in treating neurodegenerative diseases, with GLP-1 receptor agonists showing potential. Safety, tolerability, and CNS penetration should be considered when repurposing these drugs for neurodegenerative conditions.
The current treatment options for neurodegenerative diseases in older adults rely mainly on providing symptomatic relief. Yet, it remains imperative to identify agents that slow or halt disease progression to avoid the most disabling features often associated with advanced disease stages. A potential overlap between the pathological processes involved in diabetes and neurodegeneration has been established, raising the question of whether incretin-based therapies for diabetes may also be useful in treating neurodegenerative diseases in older adults. Here, we review the different agents that belong to this class of drugs (GLP-1 receptor agonists, dual/triple receptor agonists, DPP-4 inhibitors) and describe the data supporting their potential role in treating neurodegenerative conditions including Parkinson's disease and Alzheimer's disease. We further discuss whether there are any distinctive properties among them, particularly in the context of safety or tolerability and CNS penetration, that might facilitate their successful repurposing as disease-modifying drugs. Proof-of-efficacy data will obviously be of the greatest importance, and this is most likely to be demonstrable in agents that reach the central nervous system and impact on neuronal GLP-1 receptors. Additionally, however, the long-term safety and tolerability (including gastrointestinal side effects and unwanted weight loss) as well as the route of administration of this class of agents may also ultimately determine success and these aspects should be considered in prioritising which approaches to subject to formal clinical trial evaluations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据